Nanobiotix is trading $33.44, down 5.12%, as a broader biotechnology selloff pressures the stock rather than a newly reported company-specific setback. - The XBI biotech ETF is down 2.04% during the September 24, 2026 session, as rising Treasury yields, inflation concerns and weaker overall market sentiment weigh on growth-oriented healthcare stocks. - Nanobiotix’s September 14 company release reported encouraging clinical results; no new release dated September 24 was identified.